Claims
- 1. A granular pharmaceutical preparation comprising drug-containing granules or pellets wherein the drug in the drug-containing granules or pellets is selected from the group consisting of nicardipine, amosulalol and pharmaceutically acceptable salts thereof, said granules or pellets being coated with a drug release control composition, said composition containing:
- (a) 60-85 parts by weight of copolymer of ethyl acrylate, methyl methacrylate and trimethylammonioethyl methacrylate chloride in a molar ration of 1:2:0.1; and a total of 15-40 parts by weight of a component (b) and (c) wherein
- (b) is a copolymer of methyl methacrylate and methacrylic acid in a molar ratio of 1:1;
- (c) is a copolymer of methyl methacrylate and methacrylic acid in a molar ratio of 2:1; and optionally
- (d) a copolymer of ethyl acrylate, methyl methacrylate and trimethylammonioethyl methacrylate chloride in a molar ratio of 1:2:0.2, the amount of (d) being 0-30 parts by weight per 100 parts of the combined weight of (a)+(b)+(c).
- 2. The granular pharmaceutical preparations of claim 1 wherein the drug in the drug-containing granules or pellets is nicardipine or a pharmaceutically acceptable salt thereof.
- 3. The granular pharmaceutical preparation of claim 1 wherein the drug in the drug-containing granules or pellets is amosulalol hydrochloride.
- 4. The granular pharmaceutical preparation of claim 1 which further contains other drug-containing granules or pellets.
- 5. The granular pharmaceutical preparation of claim 1 wherein the granules or pellets are comprised of fine particle nuclei coated with a mixture of said drug and at least one member selected from the group consisting of an enteric base, a gastric juice-soluble base and a surface active agent.
- 6. The granular pharmaceutical preparation of claim 5 wherein the enteric base is selected from the group consisting of hydroxypropylmethylcellulosephthalate, methylmethacrylate/methacrylic acid copolymer, cellulose acetate phthalate and shellac.
- 7. The granular pharmaceutical preparation of claim 5 wherein the gastric juice-soluble base is selected from the group consisting of hydroxypropylcellulose, polyethylene glycol, methylcellulose and hydroxypropylmethylcellulose.
- 8. The granular pharmaceutical preparation of claim 5 wherein the surface active agent is selected from the group consisting of polyoxyethylenesorbitan monooleate, polyoxyethylene alkyl ether and polyoxyethylene hardened castor oil.
- 9. The granular pharmaceutical preparation of claim 1 wherein the granules or pellets are comprised of said drug and a pharmaceutically acceptable organic acid.
- 10. The granular pharmaceutical preparation of claim 9 wherein the organic acid is selected from the group consisting of citric acid and tartaric acid.
Priority Claims (1)
Number |
Date |
Country |
Kind |
1-58684 |
Oct 1989 |
JPX |
|
Parent Case Info
This application is a continuation of application Ser. No. 617,499, filed Nov. 23, 1990, abandoned, which is a division of application Ser. No. 490,831, filed Mar. 8, 1990, U.S. Pat. No. 5,028,664.
US Referenced Citations (6)
Foreign Referenced Citations (1)
Number |
Date |
Country |
0253173 |
Jun 1987 |
EPX |
Divisions (1)
|
Number |
Date |
Country |
Parent |
490831 |
Mar 1990 |
|
Continuations (1)
|
Number |
Date |
Country |
Parent |
617499 |
Nov 1990 |
|